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Abstract
 
To gain insight into the inability of newborns to mount efficient Th1 responses, we analyzed the
molecular basis of defective IL-12(p35) expression in human neonatal monocyte-derived dendritic
cells (DCs). Determination of IL-12(p35) pre-mRNA levels by real-time RT-PCR revealed that
transcriptional activation of the gene in lipopolysaccharide-stimulated neonatal DCs was strongly
impaired compared with adult DCs. We next showed that p50/p65 and p65/p65 dimers interact
with kB#1 site, a critical cis-acting element of the 
 
IL-12(p35)
 
 promoter. We found that LPS-
induced p65 activation was similar in adult and newborn DCs. Likewise, in vitro binding activity
to the Sp1#1 site, previously shown to be critical for 
 
IL-12(p35)
 
 gene activation, did not differ in
adults and newborns. Since the accessibility to this Sp1#1 site was found to depend on nucleosome
remodeling, we used a chromatin accessibility assay to compare remodeling of the relevant nucleo-
some (nuc-2) in adult and neonatal DCs. We observed that nuc-2 remodeling in neonatal DCs
was profoundly impaired in response to lipopolysaccharide. Both nuc-2 remodeling and IL-12(p35)
gene transcription were restored upon addition of recombinant interferon-
 
 
 
. We conclude that
IL-12(p35) transcriptional repression in neonatal DCs takes place at the chromatin level.
Key words: cord blood • newborn • nucleosome • NF-
 
 
 
B • Sp1
 
Introduction
 
The fetal immune system is deficient in the generation of
Th1-type responses. During pregnancy, this deficiency
protects the fetus against potentially harmful inflammatory
reactions (1). However, after delivery it results in increased
susceptibility to intracellular pathogens (2) and can favor
the development of allergic disorders (3).
Inherent CD4
 
 
 
 T cell deficiencies certainly contribute to
the Th1/Th2 imbalance in early life as indicated by hyper-
methylation of specific sites in the promoter region of the
IFN-
 
 
 
 gene (4). Furthermore, there is evidence that imma-
turity of the APC compartment also contributes to impaired
T cell responses in human newborns (5–7). Indeed, we dem-
onstrated recently that neonatal monocyte-derived DCs are
deficient in the production of IL-12(p70), but not of other
cytokines, in response to LPS, CD40 ligand, or poly I:C (6).
Determination of IL-12(p40) and IL-12(p35) mRNA levels
revealed that 
 
IL-12(p35)
 
 gene expression was highly repressed
in LPS-stimulated neonatal DCs, whereas their IL-12(p40)
gene expression was not altered (6). The relevance of these
findings obtained on monocyte-derived DCs is supported by
the observation that IL-12(p70) but not IL-12(p40) produc-
tion is impaired in LPS-stimulated cord blood (8). The aim
of this study was to identify the molecular basis for impaired
IL-12(p35) expression in neonatal DCs.
 
Materials and Methods
 
Cells and Reagents.
 
DCs were generated from cord blood
mononuclear cells or PBMC as described previously (6). LPS from
 
Escherichia coli
 
 (0128: B12), 
 
 
 
-amanitin, and mithramycin were
obtained from Sigma-Aldrich. Recombinant human and murine
IFN-
 
 
 
 were purchased from Biosource Europe and Roche Diag-
nostics, respectively.
 
Plasmid Constructs.
 
The luciferase reporter p35-lucWT plas-
mid was described previously (9). The plasmid p35
 
 
 
B-luc is a de-
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rivative of p35-lucWT in which the 
 
 
 
B#1 site was altered by the
QuickChange Site-directed Mutagenesis Method (GTCCCGG-
GAAAGTCCT to GGAGCCTCAAAGGAGT).
 
RNA Purification and Real-Time RT-PCR for Determination of
IL-12(p35) pre-mRNA Levels.
 
Total RNA was extracted using a
MagnaPure LC RNA Isolation Kit (Roche Diagnostics). RT-
and real-time PCR reactions were then performed using Light-
Cycler-RNA Master Hybridization Probes (one-step procedure)
on a Lightcycler
 
®
 
 apparatus (Roche Diagnostics). To ensure
specificity for IL-12(p35) pre-mRNA, primers encompassing the
first intron-exon boundary were used. Controls were included
for all reactions to exclude amplification of contaminating geno-
mic DNA. To correlate the Ct values to copy number, a standard
curve was generated using serial dilutions of a plasmid containing
nucleotide (nt) 
 
 
 
2606/
 
 
 
1308 from the human 
 
IL-12(p35)
 
 gene.
Primer sequences are listed in Table S1 (available at http://
www.jem.org/cgi/content/full/jem.20031272/DC1).
 
Electrophoretic Mobility Shift Assays.
 
 
 
B#1wt probe was gen-
erated by end labeling the double stranded oligonucleotide 5
 
 
 
-
AGAGTCCCGGGAAAGTCCTGCCGCGCC-3
 
 
 
 (correspond-
ing to nt 
 
 
 
68 to 
 
 
 
42), and electrophoretic mobility shift assays
(EMSAs) were performed as described previously (9). For com-
petition analysis, increasing concentrations (5–80-fold molar
excess) of unlabeled 
 
 
 
B#1wt, consensus (5
 
 
 
-AGTTGAGGG-
GACTTTCCCAGGC-3
 
 
 
) or mutated consensus (5
 
 
 
-AGTTG-
AGGCGACTTTCCCAGGC-3
 
 
 
) competitor DNA was added.
For supershift assays, antibodies against p50, p52 (both obtained
from Upstate Biotechnology), p65, RelB, c-Rel, or PU-1 (used
as a control) (obtained from Santa Cruz Biotechnology, Inc.)
were included in the binding-reaction mixture.
 
Detection of NF-
 
 
 
B DNA-binding Activity.
 
NF-
 
 
 
B binding
activity in nuclear extracts was measured with Trans-AM p65
transcription factor assay kit (Active Motif Europe). 5 
 
 
 
g of nu-
clear extracts was incubated with plate-coated NF-
 
 
 
B consensus
oligonucleotide. Plates were washed before addition of anti-p65
antibody. Antibody binding was detected with a secondary
HRP-conjugated antibody and developed with TMB substrate.
The intensity of the reaction was measured at 450 nm.
 
Transient Transfection and Luciferase Assays.
 
RAW 264.7 cells
were transfected using FuGENE™-6 (Roche Diagnostics) and
stimulated as described previously (11).
 
Indirect End Labeling.
 
Nuclei isolation, in vivo digestion with
BstXI, and DNA purification for the indirect end labeling exper-
iments were performed as described previously (10). Purified
DNA was incubated with an excess of EcoRI and analyzed by
electrophoresis on a 1.5% agarose gel. Samples were then trans-
ferred and hybridized with a [
 
32
 
P]dCTP-radiolabeled probe span-
ning nt –1610 to –890 from the 
 
IL-12(p35)
 
 gene.
 
Determination of Chromatin Accessibility by Real-Time PCR
(CHART-PCR).
 
Genomic DNA from purified nuclei was ex-
tracted using the MagNa Pure LC DNA Isolation Kit (Roche
Diagnostics). Real-time PCR reactions were then performed us-
ing LightCycler-DNA Master Hybridization Probes (Roche Di-
agnostics). The sampling of all components was fully automated
to avoid manual sampling errors. To correlate the Ct values to
copy number, a standard curve was generated using serial dilu-
tions of a plasmid containing nt –2606/
 
 
 
1308 from the human
 
IL-12(p35)
 
 gene. Amplification with primer set A (encompassing
BstXI site located at nt –298) is sensitive to remodeling of nuc-2.
Increased accessibility of the region results in reduced amplifica-
tion. To normalize for DNA input amounts and for the efficiency
of BstXI digestion, an aliquot of each sample was analyzed with
primer set B (encompassing BstXI site located at nt 
 
 
 
456). Since
the region amplified by this second set of primer does not un-
dergo modification of chromatin structure upon stimulation, it
provides an excellent internal control for the experiment. Results
were then expressed as a percentage of the accessibility observed
in the unstimulated digested samples. Primer sequences are listed
in Table S1.
 
Statistical Analysis.
 
Statistical significance was evaluated by
using two-tailed Student’s 
 
t
 
 test.
 
Online Supplemental Material.
 
Table S1 displays primer se-
quences used for real-time PCR. Table S2 shows TLR4 expres-
sion in adult and neonatal DCs. Fig. S1 shows interferon regula-
tory factor (IRF)-1 activation in adult and neonatal DCs. Online
supplemental material is available at http://www.jem.org/cgi/
content/full/jem.20031272/DC1.
 
Results and Discussion
 
Impaired IL-12(p35) Gene Transcription in LPS-stimulated
Neonatal DCs.
 
As shown in Fig. 1, induction of IL-
12(p35) pre-mRNA in response to LPS alone was signifi-
cantly lower in neonatal DCs compared with adult DCs.
IL-12(p35) pre-mRNA levels were strongly up-regulated
by the addition of recombinant IFN (rIFN)-
 
 
 
 to LPS both
in neonatal and adult DCs. rIFN-
 
 
 
 alone led to a weak in-
crease in IL-12(p35) pre-mRNA levels, which was compa-
rable in both populations. These results indicate that defi-
cient LPS-induced IL-12(p70) synthesis in neonatal DCs is
related to impaired 
 
IL-12(p35)
 
 gene transcription and can
be compensated by rIFN-
 
 
 
 addition.
As TLR4 represents the main signaling receptor for LPS,
we compared its expression in adult and neonatal DCs.
TLR4 mRNA and surface expression was comparable in
both groups (Table S2, available at http://www.jem.org/
cgi/content/full/jem.20031272/DC1). Together with pre-
vious reports (6, 7), these data indicate that the deficient
IL-12(p35) production by neonatal DCs cannot be attrib-
uted to a global defect in TLR4 signaling.
Figure 1. Deficient transcriptional activation of the IL-12(p35) gene in
LPS-stimulated neonatal DCs. Adult (black bars) or neonatal DCs (white
bars) were either incubated with medium alone or stimulated with LPS (1
 g/ml) and/or rIFN-  (100 U/ml) for 5 h. IL-12(p35) pre-mRNA levels
were normalized using  -actin mRNA levels and compared with unstim-
ulated conditions. Data are shown as mean   SEM of at least eight inde-
pendent experiments on different donors. ***P   0.001 compared with
adult DCs. 
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p50/p65 and p65/p65 Dimers Interact with 
 
 
 
B#1 Site, a
Critical cis-acting Element of the IL-12(p35) Promoter.
 
Since
IL-12(p35) expression is impaired in c-Rel knockout mice
(11), we analyzed the nucleotide sequence of the 
 
p35
 
 pro-
moter region for the presence of putative 
 
 
 
B elements. We
designed a double stranded oligonucleotide, designated
 
 
 
B#1wt, encompassing a potential binding site at position
nt 
 
 
 
50/
 
 
 
64. Competition EMSAs illustrated in Fig. 2 A
indicated that protein binding in complexes A and B was
specific to NF-
 
 
 
B, since a consensus oligonucleotide (NF-
 
 
 
B cons) specifically inhibited their formation although
they were not affected by a mutated version of the NF-
 
 
 
B
consensus oligonucleotide (NF-
 
 
 
B mut). As shown in Fig.
2 B, specific binding to the 
 
 
 
B#1 site (complexes A and B)
was inducible since it required LPS stimulation. Addition
of anti-p50 antibody interfered with the formation of com-
plex B and generated a supershift complex. The anti-p65
antibody also generated a strong supershift and inhibited
the formation of both complexes A and B. No supershifted
complex was observed with anti-RelB, -cRel, -p52 or a
control antibody (Fig. 2 B). Overall, these results demon-
strate that the induction of complexes A and B upon LPS
stimulation corresponds to the formation of p65/p65 ho-
modimers and p50/p65 heterodimers, respectively.
To examine the functional role of the 
 
 
 
B#1 site in the
transcriptional activity of the 
 
p35
 
 promoter, GGG (or
GGA) to CTC mutations were introduced by site-directed
mutagenesis in the context of a reporter plasmid containing
the 
 
 
 
1121/
 
 
 
66 region of the human 
 
IL-12(p35)
 
 gene. In
RAW cells transiently transfected with either the wild-type
or the mutated reporter construct, we found that both basal
and inducible p35 promoter activities were strongly re-
duced by mutation of the 
 
 
 
B1#1 site. These results indi-
cate that the 
 
 
 
B1#1 site is a key cis-acting element for 
 
p35
 
promoter activity.
 
NF-
 
 
 
B and Sp1 Binding Activities Are Comparable in Adult
and Neonatal DCs.
 
To explore the molecular mechanisms
responsible for deficient 
 
IL-12(p35)
 
 gene expression in
neonatal DCs, we quantified Rel protein p65 activation in
LPS-stimulated adult and neonatal DCs. As shown in Fig. 3
A, p65 activation was comparable in both groups, suggest-
ing that TLR4-triggered events leading to NF-
 
 
 
B activa-
tion are functional in early life. This is consistent with the
maintained production of NF-
 
 
 
B–dependent proinflam-
matory cytokines (6).
We showed previously that Sp1 binding to the Sp1#1
and #2 sites of the 
 
p35
 
 promoter was critical for both basal
and inducible expression of the gene (9). As assessed by
EMSA experiments (Fig. 3 B), in vitro binding activity to
the Sp1#1 site was found to be constitutive in adult DCs
and was not enhanced upon activation. Importantly, no dif-
ference in binding to the Sp1#1 site was observed between
adult and neonatal DCs, even when nuclear extracts were
diluted to ensure that the assay was not saturated (Fig. 3 C).
 
Chromatin Remodeling in Adult and Neonatal DCs.
 
Since
association of transcription factors with promoter or en-
hancer regions occurs in the context of chromatin, factors
which have been identified on the basis of their in vitro
binding activities might not be able to interact with their
DNA target in vivo. Indeed, we showed recently that the
Sp1#1 binding site is located into a positioned nucleosome
(nuc-2), which is selectively and rapidly remodeled upon
activation of the 
 
p35
 
 gene (Fig. 3 D) (9). Therefore, we
compared nuc-2 remodeling in adult and neonatal DCs.
For this purpose, we first performed indirect end labeling
experiments to monitor the accessibility of the 
 
IL-12(p35)
 
promoter region to BstXI digestion in adult and neonatal
DCs. A BstXI restriction site (nt –298) is located within the
region protected by nuc-2, close to the Sp1#1 site (nt
 
 
 
301/
 
 
 
274). Two other BstXI recognition sites (nt 
 
 
 
117
and 
 
 
 
456) are located in regions of the 
 
p35
 
 locus, which
do not undergo chromatin remodeling, therefore providing
Figure 2. Physical and functional characterization of a  B site within
the p35 proximal promoter region. (A) Competition assays. Nuclear extracts
from LPS-stimulated adult DCs (10  g) were incubated with radiolabeled
 B#1wt probe in the absence or the presence of increasing concentrations of
the indicated unlabeled competitor. Three protein–DNA complexes (A–C)
were observed. (B) Supershift assays. DCs were incubated with medium
alone or activated for 2 h with LPS. Nuclear extracts were incubated with
the indicated specific antibody before adding the radiolabeled  B#1wt
probe. NS, nonspecific. (C)  B#1 site is necessary for basal and inducible
p35 promoter activity. RAW 264.7 cells were transiently transfected with
2  g p35-lucWT or p35-mut B#1 reporter plasmid and 20 ng pRL-TK
as an internal control. Promoter activities were normalized using Renilla
luciferase activities. Values represent the means   SEM of three independent
experiments performed in triplicates.Chromatin Remodeling at the IL-12(p35) Locus in Neonatal Dendritic Cells 1014
internal controls in the experiment. As seen in Fig. 4 A, ac-
cessibility to recognition site nt –298 was markedly up-reg-
ulated upon stimulation with LPS in adult DCs but not in
neonatal DCs.
Since the indirect end labeling technique does not allow
precise quantification of the remodeling process, we
adapted the chromatin accessibility (CHART)-PCR tech-
nique described by Rao et al. (12) to measure nuc-2 re-
Figure 3. Comparison of NF- B and Sp1 binding activities in adult
and neonatal DCs. (A) Assessment of NF- B p65 activation in adult and
neonatal DCs. DCs were left untreated or stimulated for 2 h with LPS.
Results are presented as mean   SEM from at least four different donors.
(B) Constitutive binding activity to the Sp1#1 site in neonatal and adult
DCs. DCs were left untreated or stimulated with LPS or LPS   IFN- 
for 2 h. Nuclear extracts (10  g protein) were then isolated and incubated
with radio-labeled Sp1#1wt probe from the p35 promoter (9). To ensure
specificity of the binding, nuclear extracts from LPS   IFN- –stimulated
adult DCs were incubated with radiolabeled Sp1#1wt probe in the presence
of a 50-fold molar excess of unlabeled Sp1 consensus (CONS) or mutated
consensus (CONS Mut) (9). The results are representative of three inde-
pendent experiments. (C) Nuclear extracts (5 and 2.5  g protein) from
adult and neonatal LPS-stimulated DCs were incubated with radiolabeled
Sp1#1wt probe from the p35 promoter. (D) Schematic representation of
the nucleosome organization of the p35 promoter. Positioned nucleo-
somes (ovals) are indicated. nuc-2 ( 310/ 160, broken lined oval) is
selectively remodeled on p35 transcriptional activation. Locations of the
Sp1#1, Sp1#2, and the  B#1 sites are shown. The BstXI cleavage sites
and the relative position of primer sets A and B, used for the CHART-
PCR experiments, are also represented.
Figure 4. Impaired nuc-2 remodeling in LPS-stimulated neonatal DCs.
Accessibility of the IL-12(p35) promoter region protected by nuc-2 to BstXI
was assessed by indirect end labeling and CHART-PCR. Adult and neonatal
DCs were incubated with medium alone or stimulated with LPS and/or
IFN-  for 3 h. Intact nuclei were incubated with BstXI. (A) After genomic
DNA purification and in vitro digestion with EcoRI, DNA samples were
analyzed by Southern blotting and the indirect end labeling technique. The
results are representative of five independent experiments performed with
different blood donors. The different BstXI restriction sites located in regions
of the p35 locus (nt –298,  117,  456) are indicated by arrows. (B) For
CHART-PCR assays, genomic DNA samples were subjected to real-time
analysis using primer sets A and B as described in Materials and Methods.
Results are expressed as a percentage of the accessibility observed in the un-
stimulated digested samples. Data shown are the mean   SEM obtained
from 9 neonatal and 15 adult samples. ***P   0.001 compared with adult
DCs. NS, not significant. (C) nuc-2 remodeling is insensitive to  -amanitin
or mithramycin. Adult DCs were pretreated or not with  -amanitin (5  g/
ml) or mithramycin (20 nM) for 1 h. Cells were then incubated with
medium alone or stimulated with LPS and IFN-  for 5 h (real-time RT-
PCR experiments, left) or 3 h (CHART-PCR experiments, right).Goriely et al. Brief Definitive Report 1015
modeling in the p35 promoter region. In these experi-
ments, purified genomic DNA from BstXI-digested nuclei
was subjected to real-time PCR amplification with primers
encompassing the enzyme restriction site. Calculation of
the copy numbers and normalization of the results are de-
scribed in Materials and Methods. As seen in Fig. 4 B, stim-
ulation of adult DCs by LPS or IFN-  alone led to an in-
crease in chromatin accessibility of the region protected by
nuc-2 of  30%. When rIFN-  was added to LPS, mean
accessibility increased by up to 45%. In neonatal DCs,
nuc-2 remodeling in response to LPS was strongly im-
paired, confirming the data obtained using the indirect end
labeling technique. Upon stimulation with rIFN-  alone
or in combination with LPS, the response of neonatal DCs
was not significantly different from that of adult DCs. To
exclude that impaired nuc-2 remodeling in neonatal DCs
was the result rather than the cause of reduced p35 gene
expression, we suppressed RNA polymerase II activity us-
ing  -amanitin. Transcription in adult DCs pretreated with
this reagent was inhibited by  95% (Fig. 4 C). However,
this treatment had no effect on nuc-2 remodeling induced
by LPS   IFN- . To further determine whether nuc-2 re-
modeling requires Sp1 binding, DCs were incubated with
mithramycin, an agent that competes with Sp1 binding to
DNA (13). As shown in Fig. 4 C, mithramycin did not
prevent chromatin remodeling although it strongly inhib-
ited IL-12(p35) transcription in response to LPS   IFN- 
stimulation, confirming that Sp1 binding is required for in-
ducible p35 gene expression. Together with previous find-
ings showing that remodeling precedes p35 mRNA syn-
thesis (9), these data strongly suggest that nuc-2 remodeling
is a primary event during p35 gene activation. Our results
further indicate that (a) impaired IL-12(p35) gene expres-
sion by LPS-stimulated neonatal DCs is directly related to
impaired nuc-2 remodeling and (b) this deficiency can be
overcome by IFN- -induced signals.
To the best of our knowledge, these observations repre-
sent the first evidence that a defect in chromatin remodeling
contributes to the immaturity of the newborn immune sys-
tem. Restriction of Th1 responses in utero might be essen-
tial for the normal development of the fetus (1). Together
with hypermethylation of the IFN-  promoter in neonatal
CD4 CD45RA  T cells (4), depressed nucleosomal re-
modeling at the IL-12(p35) promoter in the neonatal DC
compartment might represent an important control mecha-
nism to prevent detrimental Th1 lineage development in
early life. Interestingly, depressed IFN-  production by
neonatal CD4  T cells could contribute to limit IL-12 syn-
thesis by DCs as the addition of IFN-  to LPS-stimulated
neonatal DCs strongly activates their expression of the IL-
12(p35) gene (Fig. 1). IFN-  stimulation of adult or neona-
tal DCs readily induces chromatin remodeling of the p35
gene without activating its transcription. Therefore, one
might speculate that IFN-  restores LPS-induced p35 pro-
duction in neonatal DCs through its action on chromatin
remodeling. It was shown recently that IRF-1 is recruited
to the p35 promoter in response to IFN-  (14). Interest-
ingly, this IRF-E site is located within the region protected
by nuc-2. We found no significant difference in IRF-1 acti-
vation between neonatal and adult DCs (Fig. S1, available at
http://www.jem.org/cgi/content/full/jem.20031272/DC1).
In the absence of TLR4 activation, IFN- –induced nuc-2
remodeling could be mediated by STAT-1, as described for
CIITA promoter IV (15) or by IRF-1 itself. We conclude
that understanding the mechanisms involved in nuc-2
remodeling might be crucial to our knowledge of the im-
mune status of the human newborn and for the develop-
ment of new vaccine strategies dependent on the produc-
tion of IL-12 during the neonatal period.
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